Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients

  • End date
    May 25, 2025
  • participants needed
  • sponsor
    King Faisal Specialist Hospital & Research Center
Updated on 25 February 2021



Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not fully investigated


To compare different induction therapeutic strategies with 2 doses of Basiliximab vs. no induction) in low immunologic risk kidney transplant recipients as per KFSHRC protocol (Appendix 2)


Prospective, randomized, double blind, non-inferiority, controlled clinical trial

Expected Outcomes:

  1. Primary outcomes:

Biopsy proven acute rejection within first year following transplant

2. Secondary outcomes:

  1. Patient and graft survival at 1 year
  2. Estimated glomerular filtration rate (eGFR) at 6 months and at 12 months
  3. Emergence of de novo donor specific antibodies (DSAs)

Condition Organ Transplantation, Renal transplant, Organ Transplant - Pediatric, Organ Transplant, Kidney Transplantation, kidney transplant, renal transplantation, kidney transplants
Treatment Normal saline, Basiliximab 20 milligram [Simulect]
Clinical Study IdentifierNCT04404127
SponsorKing Faisal Specialist Hospital & Research Center
Last Modified on25 February 2021


Yes No Not Sure

Inclusion Criteria

Male or female 18 years
Living donor
Low immunological risk (defined as)
First (primary) transplant
4 antigen mismatches (HLA matching scheme)
Negative HLA Ab screening

Exclusion Criteria

High immunological risk
HLA identical or zero mismatched transplants
Receiving cyclosporin as primary maintenance immunosuppressant
Human immunodeficiency virus (HIV) co-infection
Pregnant or nursing female
Has received an investigational medication within the past 30 days
Has a known contraindication to the administration of Basiliximab
Suspected or known to have a serious infection
Multi-organ transplant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note